|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
353.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sevillano J, López-Pérez IC, Herrera E, Del Pilar Ramos M, Bocos C. Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates. Biochem J. 2005 Aug 1;389(Pt 3):913-8. doi: 10.1042/BJ20041837. PMID: 15810879; PMCID: PMC1180742.
2: Stevenson RW, McPherson RK, Persson LM, Genereux PE, Swick AG, Spitzer J, Herbst JJ, Andrews KM, Kreutter DK, Gibbs EM. The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet. Diabetes. 1996 Jan;45(1):60-6. doi: 10.2337/diab.45.1.60. PMID: 8522061.
3: Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, et al. Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes. 1990 Oct;39(10):1218-27. doi: 10.2337/diab.39.10.1218. PMID: 2210074.
4: McKay NG, Kinsella JM, Campbell CM, Ashford ML. Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone. Br J Pharmacol. 2000 Jun;130(4):857-66. doi: 10.1038/sj.bjp.0703395. PMID: 10864893; PMCID: PMC1572145.
5: Rowe IC, Lee K, Khan RN, Ashford ML. Effect of englitazone on KATP and calcium-activated non-selective cation channels in CRI-G1 insulin-secreting cells. Br J Pharmacol. 1997 Jun;121(3):531-9. doi: 10.1038/sj.bjp.0701145. PMID: 9179397; PMCID: PMC1564701.
6: Harvey J, Ashford ML. Diazoxide- and leptin-activated K(ATP) currents exhibit differential sensitivity to englitazone and ciclazindol in the rat CRI-G1 insulin-secreting cell line. Br J Pharmacol. 1998 Aug;124(7):1557-65. doi: 10.1038/sj.bjp.0702000. PMID: 9723971; PMCID: PMC1565548.
7: Xia G, Zhuang Z, Liu LY, Schreiber SL, Melillo B, Yu JQ. Ligand-Enabled β-Methylene C(sp3 )-H Arylation of Masked Aliphatic Alcohols. Angew Chem Int Ed Engl. 2020 May 11;59(20):7783-7787. doi: 10.1002/anie.202000632. Epub 2020 Mar 11. PMID: 32050036; PMCID: PMC7219561.
8: Adams MD, Raman P, Judd RL. Comparative effects of englitazone and glyburide on gluconeogenesis and glycolysis in the isolated perfused rat liver. Biochem Pharmacol. 1998 Jun 1;55(11):1915-20. doi: 10.1016/s0006-2952(98)00052-5. PMID: 9714310.
9: Stevenson RW, Kreutter DK, Andrews KM, Genereux PE, Gibbs EM. Possibility of distinct insulin-signaling pathways beyond phosphatidylinositol 3-kinase- mediating glucose transport and lipogenesis. Diabetes. 1998 Feb;47(2):179-85. doi: 10.2337/diab.47.2.179. PMID: 9519710.
10: Stevenson RW, McPherson RK, Genereux PE, Danbury BH, Kreutter DK. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism. 1991 Dec;40(12):1268-74. doi: 10.1016/0026-0495(91)90027-t. PMID: 1961119.
